The lipooligosaccharide (LOS) of Haemophilus influenzae contains sialylated glycoforms, and a sialyltransferase, Lic3A, has been previously identified. We report evidence for two additional sialyltransferases, SiaA, and LsgB, that affect N-acetyllactosamine containing glycoforms. Mutations in genes we have designated siaA and lsgB affected only the sialylated glycoforms containing N-acetylhexosamine. A mutation in siaA resulted in the loss of glycoforms terminating in sialyl-N-acetylhexosamine and the appearance of higher molecular weight glycoforms, containing the addition of phosphoethanolamine, N-acetylgalactosamine, and N-acetylneuraminic acid. Chromosomal complementation of the siaA mutant resulted in the expression of the original sialylated LOS phenotype. A mutation in lic3A resulted in the loss of sialylation only in glycoforms lacking N-acetylhexosamine and had no effect on sialylation of the terminal N-acetyllactosamine epitope. A double mutant in siaA and lic3A resulted in the complete loss of sialylation of the terminal N-acetyllactosamine epitope and expression of the higher molecular weight sialylated glycoforms seen in the siaA mutant. Mutation of lsgB resulted in persistence of sialylated glycoforms but a reduction in N-acetyllactosamine containing glycoforms. A triple mutant of siaA, lic3A, and lsgB contained no sialylated glycoforms. These results demonstrate that the sialylation of the LOS of H. influenzae is a complex process involving multiple sialyltransferases.
Haemophilus influenzae frequently colonizes the human nasopharynx. Up to 80% of the population harbor this organism as part of their normal flora (1) . Although normally an innocuous inhabitant of the upper respiratory tract, H. influenzae is an opportunistic pathogen. The diseases caused by the organism can be ordered in two groups based on the presence or absence of a capsule. Encapsulated or typeable organisms, which range from capsule types a-f, can cause systemic infections such as bacteremia, septicemia, and bacterial meningitis (1, 2) . Of the various encapsulated types, H. influenzae type b has been associated most often with pathogenesis (2) . The nonencapsulated or nontypeable (NTHi) 1 strains of H. influenzae cause more localized infections, such as chronic bronchitis or otitis media, and rarely cause systemic infections (3, 4) .
There are a number of virulence factors associated with both H. influenzae type b and NTHi that contribute to their pathogenesis, one of these being the lipooligosaccharide (LOS) (5) (6) (7) (8) (9) . LOS is a complex glycolipid containing three main regions: lipid A, core, and a variable branched region (10) . The core region is a conserved structure containing a phosphorylated Kdo residue linked to three heptose residues, whereas the variable branched region contains a heterogeneous mix of hexoses and N-acetylhexosamines as well as other factors, such as phosphoethanolamine (PEA), phosphorylcholine, and NeuAc (11) (12) (13) (14) (15) (16) . LOS differs from its enterobacterial counterpart, lipopolysaccharide, in that the variable branched region or Oantigen is a nonrepeating unit (10) . A great deal of work has been undertaken to understand the biosynthesis and role of LOS in pathogenesis (10) .
H. influenzae LOS is very heterogeneous and contains a number of phase-varying epitopes (17, 18) . Phase variation is known at least in part to occur through a process of slippedstrand mispairing (19) . Three well characterized loci involved in LOS expression and phase variation, designated lic1, lic2, and lic3, phase-vary through this mechanism (20 -22) . Phase variation may play a role for the bacterium in the evasion of the host immune response. LOS structures have also been found to mimic human blood group antigens, such as the P k antigen and paragloboside (23) . This may be another method for bacterial immune evasion.
The lsg (lipooligosaccharide synthesis genes) locus is another region involved in LOS biosynthesis (24) . Seven genes are in the locus, six of which have identity to various glycosyltransferases and one that acts as a regulator (25) . This locus is not controlled by the slipped strand mispairing mechanism. Through studies expressing chimeric Haemophilus structures in Escherichia coli lipopolysaccharide, we know that this locus is involved in the expression of a terminal N-acetyllactosamine structure (25) . One of the genes in this locus, lsgB, has homology (27% identity, 46% similarity) to the sialyltransferase in Neisseria meningitidis. In various Neisseria and Haemophilus species, a terminal N-acetyllactosamine structure has been shown to be an acceptor for sialylation (23, 26, 27) .
NeuAc is a constituent of the LOS in about half of the H. influenzae strains tested (23, 28) . Sialylation in H. influenzae has been shown to affect its ability to evade the lytic effects of human serum (28, 29) . Two genes have been identified that are involved in LOS sialylation, siaB and lic3A (28, 29) . siaB is a CMP-NeuAc synthetase, and a mutation in this gene eliminates all sialylation (28) . The second gene, lic3A, has been shown to function as an ␣2-3-sialyltransferase, responsible for sialylating terminal lactose structures. The lic3A gene has about 40% identity to cstII from Campylobacter jejuni (29) . This gene is one of two sialyltransferases identified in this organism (30) . A mutation in lic3A in one strain of H. influenzae still contained sialylated glycoforms, indicating the possibility of a second sialyltransferase in this organism (29) . H. influenzae contains a homologue to a sialyltransferase from Haemophilus ducreyi, which is designated as HI0871 in the H. influenzae Rd genome data base (31) . In a study looking at a number of genes from H. influenzae and their possible role in LOS biosynthesis, no function for this gene (designated orfY) was found (32) . This gene, which we call siaA, was studied for its possible role in LOS sialylation. We report evidence that siaA is a sialyltransferase in H. influenzae and that lsgB is required for the biosynthesis of a third, distinct sialylated glycoform, and our evidence strongly suggests that LsgB is the third sialyltransferase.
EXPERIMENTAL PROCEDURES
Bacterial Strains and Growth Conditions-All bacterial strains and plasmids used in this study are listed in Table I . Parental strains 2019, A2, and their derivatives were grown on brain heart infusion agar (Difco) supplemented with 10 g/ml ␤-nicotinamide adenine dinucleotide (Sigma) and 10 g/ml hemin (ICN Biochemicals) at 37°C. When appropriate, 15 g/ml ribostamycin (Sigma) (a kanamycin analogue), 1 g/ml chloramphenicol, 15 g/ml spectinomycin, and 20 g/ml NeuAc (Sigma) were added to the media.
DNA Isolation and Manipulation-Chromosomal DNA was isolated using standard protocols. Restriction enzymes were purchased from either New England Biolabs or Promega. Polymerase chain reactions (PCRs) were performed with either Taq DNA Polymerase (Roche Molecular Biochemicals) or the Expand Long Template kit (Roche Molecular Biochemicals). All plasmid constructs were maintained in either E. coli DH5␣ or DH10B (Invitrogen). Gel purification was performed with SeaPlaque GTG-agarose (BioWittaker Molecular Applications) using standard protocols.
Southern Hybridization-DNA was digested to completion with the appropriate restriction enzymes, fractionated in 0.7% agarose gels, and transferred to Hybond-N nylon membranes (Amersham Biosciences). Southern blots were hybridized with probes generated by the random primed digoxygenin DNA labeling kit (Roche Molecular Biochemicals). All blots were processed by following the digoxygenin protocols. Chemiluminescent detection was performed with Kodak XAR-5 or BMR-1 film (Eastman Kodak Co.).
DNA Sequencing-DNA was sequenced with an Applied Biosystems (33) , an open reading frame (ORF) in the H. influenzae Rd data base named HI0871 was identified, which contained 48% identity and 59% similarity over the length of the predicted protein sequence. HI0871 was renamed siaA. Primers were made to amplify siaA and some flanking DNA from strain 2019 based on the Rd sequence from the TIGR data base (available on the World Wide Web at www.tigr.org/). A 4.3-kb product was amplified using the Expand Long Template PCR kit (Roche Molecular Biochemicals) and primers HSTR8 (5Ј-CTG CAA AAT ACA GAT AAA GCA ACA CTG GGG-3Ј) and HSTR9 (5Ј-CAG CGG CAA GAA ATA TAG GGT TAG AAA AAG C-3Ј), which was then TA-cloned into pCR2.1 (Invitrogen), forming pHS89-21. This insert was sequenced (accession number AY061634). The 4.3-kb DNA fragment was then subcloned into the EcoRI site of pBluescript KS II Ϫ (Stratagene), forming pHS89-103. The insertional mutant of siaA was constructed by cloning a PstI-digested kanamycin antibiotic resistance gene from pBSL86 into a unique NsiI site in the middle of siaA, forming pHS89-103K6. The orientation of the kanamycin gene was discerned with a restriction digest and was found to be transcribed in the same direction as siaA (data not shown). pHS89-103K6 was linearized with ScaI and transformed into strains A2 and 276.4 (34) . Transformants were obtained and analyzed using both PCR with internal siaA primers HSTR1 (5Ј-GAT GTT ATT TTT ATT TTT GTT A-3Ј) and HSTR2 (5Ј-ACT TAG GGT GTA TTT TGG TTC C-3Ј) and Southern blots (data not shown).
Cloning of siaB and Mutant Construction of A2SB-Primers SiaBU2 (5Ј-CGG ACT ATC ATA ACG GGC-3Ј) and SiaBD2 (5Ј-CTC AGA ATT CGG GCT TCG-3Ј) were designed based on the H. influenzae Rd genome. A 1.5-kb DNA fragment was amplified from NTHi 2019 and TA-cloned into pCR2.1, and both DNA strands were sequenced. This new plasmid, called pSiaB2, contained a 675-base pair ORF with 95% identity to HI1279 from H. influenzae Rd. This plasmid was digested with SspI, which cuts at a unique site after nucleotide 276. A spectinomycin resistance cassette gene was digested with SmaI from pABR3 and ligated into the SspI site of pSiaB2, forming pSiaB2Spec. This new construct was digested with NotI to linearize the DNA and then transformed into strain A2 using the MIV method (34) . Transformants were obtained and tested using PCR and Southern hybridization to confirm the proper insertion of the spectinomycin cassette in siaB (data not shown).
Cloning of lsgB and Mutant Construction of A2lsgB and A2STFL3AlsgB-A 3456-bp BamHI-BsbI fragment of H. influenzae A2 DNA containing lsgA, -B, -C, and -D was cloned into pGEM3zfϩ. A 502-bp (BsrGI-XcmI) region of lsgB was deleted and replaced by an erythromycin cassette. This new plasmid was called pGEMLOS2ABCDerm. This plasmid was digested with NdeI and transformed into strains A2 and A2STFL3A using the MIV method (34) . Transformants were obtained and tested using PCR and Southern hybridization to confirm the proper insertion of the erythromycin cassette in lsgB (data not shown). The mutants were designated strains A2lsgB and A2STFL3AlsgB.
TA Cloning of ira from Strain 2019 -Primers iraF (5Ј-AGG GGG ATA AAA CAA AGG-3Ј) and iraR (5Ј-GGC AAG TCC CTG TTC AAA-3Ј) for PCR were designed from the published H. influenzae Rd genome. These primers were used to amplify an intergenic region between bases 794506 and 796038. Amplification resulted in a PCR product of ϳ1.6 kb from the genome of NTHi strain 2019. The product was then cloned into the vector pTAV1 via TA cloning. The nucleotide sequence of the cloned fragment was elucidated and compared with sequences included in the genome data base. The resolved consensus sequence was entered into MacVector to identify useful restriction sites. One SphI site was predicted that would cut the cloned region into 711-and 822-base fragments and could be used to linearize pIRA. The presence of the unique SphI site was verified by restriction endonuclease digestion of pIRA.
Construction of pIRACM-The plasmid pCMR containing a chloramphenicol resistance cassette possessing the consensus uptake sequence for Haemophilus transformation was kindly provided by Dr. Terrence Stull (35) . To obtain the necessary SphI sites, the chloramphenicol resistance cassette was excised from pCMR using PstI, gel-purified, and then ligated into the vector pBSL15 that had been previously cut with PstI. The resulting plasmid was named pHiCM1. Finally, the chloramphenicol resistance cassette was excised from pHiCM1 by cleavage with SphI, gel-purified, and ligated into the SphI site of pIRA, forming pIRACM. Insertion was confirmed by PCR and by sequencing the cloning junctions.
Complementation of A2STF-A 2.5-kb EcoRV DNA fragment was excised from pHS89-103, gel-purified, and blunt end-ligated into the SfoI site of pIRACM, forming pSAIRCM. This construct was used as a template for PCR using primers iraR and iraF, and the resulting PCR product was transformed into A2STF using the MIV method (34) . Transformants were selected for with both kanamycin and chloramphenicol. Verification that both the full-length and the mutant forms of siaA were present on the chromosome was performed with PCR using primers HSTR1 and HSTR2 and with Southern blots (data not shown). A control strain was constructed in a similar fashion by transforming A2STF with pIRA. The insertion into the chromosome was confirmed with Southern blots, and the resultant strain was named A2STFIRA (data not shown).
Cloning of lic3A and Mutant Construction of A2L3A and A2STFL3A-Primers 0352ELTU1 (5Ј-ATG TCC AAA AGC AGC CAA CCA AAT AAA CCC-3Ј) and 0352ELTL1 (5Ј-CAA CGC CGA AAT CAA CCC AAA TAG AAA GCC-3Ј) were designed using the H. influenzae Rd genome data base and a 4.6-kb DNA fragment containing the HI0352 ORF (lic3A) was amplified from strain A2 using PCR. The DNA fragment was TA-cloned into pCR2.1 and was named p0352EX. Both DNA strands were sequenced, and a unique SwaI site was found after nucleotide 683 of the 981-nucleotide lic3A sequence. A nonpolar chloramphenicol cassette (pRSM1775), which was constructed in a manner similar to that described by Menard et al. (36) using the chloramphenicol gene (cat) from pACYC184, 2 was digested with SmaI and cloned into the SwaI site of lic3A. This construct was named p0352EXCM. The nonpolar cassette contains translation stop codons in all three reading frames upstream from the start codon of cat. Five bases after the cat stop codon, there is a Shine-Dalgarno sequence followed by a start codon, which is in-frame with the remainder of the lic3A gene. The insertion sites of the chloramphenicol cassette were sequenced to ensure proper insertion and orientation. p0352EXCM was linearized by digestion with BamHI and transformed using the MIV method (34) into strains A2 and A2STF, forming strains A2L3A and A2STFL3A respectively. Proper insertion into the chromosome of these strains was confirmed with PCR amplification using primers to the lic3A sequence and Southern hybridization (data not shown).
LOS Preparation and Neuraminidase Treatment-The LOS was prepared by a modification of the Hitchcock and Brown method (37) . Organisms were grown on solid media supplemented with 20 g/ml of NeuAc. The organisms from a single plate were suspended in 2 ml of phosphate-buffered saline buffer to a final A 650 of 0.9. They were washed twice with phosphate-buffered saline, resuspended in 200 l of lysis buffer (0.06 M Tris base, 10 mM EDTA, 2.0% SDS, pH 6.8), and incubated in a boiling water bath for 5-10 min. The samples were allowed to cool, and 30 l of a proteinase K solution (2.5 mg/ml diluted in lysis buffer; Sigma) was added to 150 l of the boiled sample. The samples were incubated at 37°C for 16 -24 h. The LOS was precipitated by adding one-tenth volume of 3 M sodium acetate and 2 volumes of 100% ethanol, put on dry ice for 10 min or in a Ϫ80°C freezer for 1 h, and then centrifuged at 15,000 ϫ g for 5 min. The samples were washed twice with 70% ethanol and brought up in double distilled H 2 O to a final volume of 180 l. For SDS-PAGE gel analysis, 1-5 l (ϳ0.5-2.5 g of LOS) of a typical preparation was treated with 0.5 milliunits of neuraminidase purified from Vibrio cholerae (Roche Molecular Biochemicals) in neuraminidase buffer (0.15 M NaCl, 4 mM CaCl 2 , pH 5.5) and incubated at 37°C for 2 h.
SDS-PAGE, Silver Staining, and Western Blotting-SDS-PAGE gels were prepared as described by Lesse et al. (38) . The gel was loaded with 0.5-1 l from each LOS preparation (ϳ0.25-0.5 g of LOS). Silver staining was performed by the method of Tsai and Frasch (39) . The Western blot was performed by the method of Towbin (40) . The monoclonal antibody 3F11 recognizes a terminal N-acetyllactosamine structure and has been characterized previously (41) . Detection of the antibody was performed using a peroxidase-labeled goat anti-mouse secondary antibody (Kirkegaard and Perry Laboratories) and Super Signal West Pico Chemiluminescent Substrate (Pierce). LOS from N. gonorrhoeae strain PID2 was used as a molecular weight standard (42) .
Whole-cell 3F11 ELISA-A whole-cell enzyme-linked immunosorbent assay (ELISA) was performed using the monoclonal antibody 3F11 and a modified method of Abdillahi and Poolman (43) . Whole bacteria were harvested from plates containing 20 g/ml of NeuAc (Sigma), suspended in phosphate-buffered saline, and washed twice. The cell suspensions were diluted with double-distilled H 2 O to an A 600 of 0.150. 100 l of the cell suspension was added to the wells of flat bottom high binding polystyrene 96-well plates (Costar) and allowed to dry completely at 37°C. Unbound material was removed by rinsing the plates with wash buffer (0.12 M sodium acetate, 0.15 M NaCl, 0.05% Tween 20) . Half of the wells were treated with neuraminidase from V. cholerae (Roche Molecular Biochemicals) in neuraminidase buffer (0.15 M NaCl, 4 mM CaCl 2 , pH 5.5), and the other half were incubated in neuraminidase buffer alone for 6 h at 37°C in a humidified chamber. The plates were washed again, and 100 l of the monoclonal antibody 3F11 in antibody buffer (0.15 M NaCl, 10 mM Tris, pH 7.4, 0.3% Tween 20) was serially diluted 2-fold from a starting dilution of 1:40. The plates were incubated at 25°C overnight. The plates were washed, and 100 l of a 1:2000 dilution of goat anti-mouse IgM phosphatase-conjugated secondary antibody (Kirkegaard and Perry Laboratories) was added to each well and allowed to incubate at 25°C for 1 h. The plates were washed, and 100 l of developer (1 mg/ml p-nitrophenyl phosphate (Sigma), 0.96% diethanolamine, 2 mM MgCl 2 , pH 10.0) was added to each well. The samples were allowed to develop for 30 min, and 50 l of 4 N NaOH was added to each well to quench the reaction. The plates were read at 405 nm with a Bio-Tec Instruments EL 311SX microplate reader.
Preparation of O-Deacylated Lipooligosaccharides (O-LOS) and
Neuraminidase Treatment-To make the LOS more amenable for mass spectrometric analysis, O-linked fatty acids were removed from the lipid A moiety. The crude LOS (ϳ90 g, from a single plate) was incubated in anhydrous hydrazine (50 l; Sigma) at 37°C for 25 min in a microcentrifuge tube with occasional sonication. Samples were cooled at Ϫ10°C for 10 min prior to and after the addition of ice-cold acetone (300 l; Aldrich). The quenched reaction mixture was centrifuged (12,000 ϫ g) for 45 min at 4°C. The supernatant was removed, and the pelleted O-LOS was dissolved in MilliQ water (40 l) and evaporated on a speed vacuum system. To remove salts and other low molecular weight contaminants, the O-LOS (ϳ10 -20 g) was suspended on a nitrocellulose membrane (type VS, 0.025 m; Millipore Corp.) over water for 1 h. The desalted O-LOS was removed from the membrane, concentrated with a speed vacuum system, and analyzed by matrixassisted laser desorption ionization-mass spectrometry (MALDI-MS). For removal of neuraminic acid, the O-LOS (ϳ10 -20 g) was digested in 10 mM ammonium acetate, pH 6.0, with immobilized neuraminidase from Clostridium perfringens (type VI; 80 milliunits) for 20 h at 30°C. The enzyme was pelleted by centrifugation, and the supernatant (15 l) was transferred to a nitrocellulose membrane for drop dialysis. The desialylated O-LOS was also concentrated and analyzed by MALDI-MS. Table II ) and the prompt fragment for lipid A (m/z ϭ 952.0). All masses are given as their average values.
MALDI-MS of O-LOS-Dowex

Exoglycosidase Treatments of O-LOS-To sequence nonreducing terminal saccharides, O-LOS samples were treated with exoglycosidases.
The following enzymes were used in these experiments: ␣-galactosidase from Mortierella vinacea (Seikagaku Corp.) or from green coffee beans (Glyko, Inc.), ␤-galactosidase from jack bean meal (Glyko, Inc.), ␤-Nacetylhexosaminidase from jack bean meal (Glyko), ␣-N-acetylgalactosaminidase from chicken liver (Sigma), ␣-glucosidase from Bacillus stearothemophilus (Sigma), ␤-glucosidase from almonds (Sigma), and immobilized neuraminidase from C. perfringens, type VI (Sigma). In general, enzyme reactions were run in 25-50 mM ammonium acetate buffer, at pH 4.5 or 6.0, depending on the enzyme (pH 4.5 for the three-enzyme mixture consisting of ␣-galactosidase, ␤-galactosidase, and ␤-N-acetylhexosaminidase). The immobilized neuraminidase was used as described above, except that in these experiments the incubation temperature was 37°C. Soluble enzyme concentrations were typically in the range of 5-10 units/ml, and total O-LOS concentrations were estimated to be in the range of ϳ100 -200 M. For the 276.4STF sample, the minor acceptor glycoform of interest was estimated to represent Յ1% of the total O-LOS mixture, making its concentration in the enzyme digest reactions on the order of ϳ1-2 M.
Various sequences of enzyme digests were carried out, generally starting with the O-LOS from 1-1.5 plates' worth of bacteria, in a reaction volume of 60 -90 l. Digests were incubated at 37°C for 20 -24 h. Except in the case of the immobilized neuraminidase, reactions were stopped by heating in a boiling water bath for 3 min. After quenching, reaction mixtures were typically delivered to prewashed Microcon YM-10 filter units (Millipore) and spun at 10,000 ϫ g for 5-15 min, depending on the reaction volumes. Samples were then washed with several 50 -100-l aliquots of MilliQ water, totaling about 400 l. Retentates were recovered by inverting the filters and centrifuging at low speed. Filters were washed with three portions of 20 -40 l of MilliQ water, and the washings were combined with the retentates and evaporated to dryness on a speed vacuum system. Because of its tendency to aggregate in solution, the O-LOS was recovered in the retentate fraction using these membrane filters. Samples were then redissolved in MilliQ water for MALDI-MS analysis as described above.
Dephosphorylation of O-LOS-O-LOS
samples were dephosphorylated by treatment with 48% aqueous HF for 16 h at 4°C. HF was removed under vacuum using an in-line NaOH trap. Samples were then redissolved in a small volume of MilliQ water and evaporated to dryness on a speed vacuum system.
RESULTS
Cloning and Mutagenesis of siaA-The ORF HI0871 from the H. influenzae Rd genome data base encodes a predicted protein of 306 amino acids. This protein sequence has 48% identity and 59% similarity along the entire length of the recently identified Lst protein from H. ducreyi (33) . Lst is the sialyltransferase responsible for the addition of NeuAc to galactose of a terminal N-acetyllactosamine moiety of the LOS (33) . Based on the Rd sequence, primers were made to amplify the HI0871 ORF and about 1.5 kb of flanking sequence on either side of the ORF. The primers were able to amplify a DNA fragment of similar expected size from strains Rd, 2019, and A2. The DNA fragment from strain 2019 was sequenced in its entirety and the gene order was found to be similar but not identical to the Rd sequence. The DNA fragment contained the 3Ј partial sequence of HI0868, the full-length HI0871 (renamed siaA), and the 5Ј partial sequence of HI0872 (wbaP homologue, formerly rfbP). There was 46% identity and 57% similarity between the predicted proteins of Lst from H. ducreyi and SiaA from NTHi 2019 and 58% identity and 70% similarity between the predicted proteins of SiaA from NTHi 2019 and HI0871.
There is a five-base overlap at the 3Ј-end of siaA and the 5Ј-end of wbaP. HI0869 contained an insertion after position 533 causing a frameshift resulting in an extension of the ORF. In addition to this, there was a small ORF (ORF1) upstream of siaA that was not present in the Rd sequence. Both HI0869 and ORF1 do not have any identity to any known genes in the current data bases. An insertional mutation was made in siaA of strains A2 and 276.4 by inserting a kanamycin cassette from pBSL86 into a NsiI site in the middle of the gene. This construct was called pHS89-103K6. Restriction digest analysis demonstrated that the kanamycin cassette, which does not contain a transcriptional termination sequence, was inserted in the same orientation as siaA. The transformation of strains A2 and 276.4 with pHS89-103K6 employing the MIV method (34) yielded numerous transformants. The mutant strains from A2 and 276.4 were named A2STF and 276.4STF, respectively. PCR analysis using probes that amplify an intergenic region of siaA, along with Southern hybridization, confirmed the single insertion of the kanamycin cassette in siaA of both strains A2STF and 276.4STF.
Identification of LOS Glycoforms in H. influenzae A2-Prior to investigating the effects of inactivating genes responsible for LOS biosynthesis in H.
influenzae, the population of glycoforms assembled by stain A2 was assessed with MALDI-MS in the negative ion mode. All observed molecular ions and the proposed LOS compositions for structures containing a minimum core structure of lipid A linked to a phosphorylated Kdo and three heptoses are summarized in Table II . Letters represent individual glycoforms to which NeuAc (each denoted by an asterisk) and 1-3 PEAs (denoted by subscripts) are added. MALDI-MS analysis of the O-LOS revealed that the A2 strain expresses an even more complex mixture of glycoforms on its outer membrane than previously thought (15) . Most structures represented extensions of the major species (B 1 and B 2 ) by up to four additional hexoses (Fig. 1, Table III ). An examination of the O-LOS proceeding the enzymatic removal of NeuAc with neuraminidase confirmed the removal of a total of eight sialylated glycoforms, which coincided with the appearance of the asialo counterparts (Fig. 1, Table III ). In general, the most abundant structures terminating with NeuAc contained a single N-acetylhexosamine and a total of six or seven hexoses (H 1 *, H 2 *, I 1 *, and I 2 *). Tandem mass spectrometric analysis of the oligosaccharide portions of the H and I glycoforms revealed the structures contained a nonreducing terminal Hex-HexNAc (consistent with a N-acetyllactosamine structure), the putative acceptor site for NeuAc. 3 Interestingly, previous investigations of the A2 strain by electrospray mass spectrometry revealed only two sialylated LOS glycoforms, each composed of a single N-acetylhexosamine and a total of five or six hexoses. This discrepancy presumably reflects the altered growth conditions, since the bacteria were grown on solid media supplemented with NeuAc in the current study (15) . Furthermore, several novel sialylated species were observed including a structure containing two NeuAcs (H 2 **) and three structures lacking N-acetylhexosamine (B 2 *, D 2 *, and E 2 *). The H 2 ** glycoform was found to be resistant to enzymatic digestion with a mixture of ␣-galactosidase, ␤-galactosidase, and ␤-N-acetylhexosaminidase, suggesting that it may be sialylated on two different branches. 4 Analysis of LOS from A2STF-MALDI-MS analysis of the LOS from the siaA mutant strain (A2STF) revealed no gross changes in the expression of LOS whose branch structures contain only hexose relative to those observed in the parental strain A2 (Fig. 1, Table III) . However, the deletion of siaA impaired the ability of the mutant strain to produce the major sialylated species (H 1 *, H 2 *, H 2 **, I 1 *, and I 2 *), leaving the putative LOS substrates of SiaA (H 1 , H 2 , I 1 , and I 2 ) unmodified. The A2STF mutant strain retained the capacity to produce the previously identified sialylated species (B 2 *, D 2 *, and E 2 *) as well as additional structures containing both NeuAc and N-acetylhexosamine (K 2 *, K 3 *, K 3 **, L 2 *, and L 3 *) that were not observed in the parental strain A2 (Fig. 1, Table III) . The emergence of the unique set of glycoforms in strain A2STF coincided with the extension of the free SiaA acceptors (H 1 , H 2 , I 1 , and I 2 ) by the addition of a ϳ617-Da moiety, suggesting the addition of HexNAc (203 Da), PEA (123 Da), and NeuAc (291 Da) (discussed below). The expression of these and other sialylated LOS structures upon the mutation of siaA provided strong evidence that multiple sialyltransferases of distinct substrate specificity reside on the outer membrane of H. influenzae strain A2.
Complementation of A2STF-To verify that the changes in the LOS glycoforms observed in A2STF were the result of a mutation in siaA, the mutation was complemented in cis. This was accomplished using the construct pSAIRCM, which was made from a 1.5-kb intergenic region identified in the Rd data base and found to be present in the chromosome of strain A2 by PCR analysis. pSAIRCM was transformed into A2STF using the MIV method (34) . A homologous recombination event at the intergenic region resulted in the incorporation of both the chloramphenicol cassette and full-length siaA genes into that region of the chromosome. It was very important to select for transformants with both kanamycin and chloramphenicol to avoid the loss of the original insertional mutant in siaA. This strain was named A2STFC.P4.
A control strain was constructed to verify that the effects seen in the complemented mutant were not due to the insertion of the chloramphenicol cassette into the intergenic region. Strain A2STFIRA was constructed in an identical manner to A2STFC.P4, with the exception that pIRACM was used instead of pSAIRCM. The insertion of the chloramphenicol cassette into the intergenic region was confirmed with Southern hybridization. There were no differences in either the growth curves or the MALDI-MS spectra when strain A2STF was compared with strain A2STFIRA. Complementation of the siaA mutation was verified by MALDI-MS analysis of LOS assembled by the A2STFC.P4 mutant strain (Fig. 1, Table III ). Reversion to the wild type phenotype was evident by the reappearance of both the minor and major sets of sialylated glycoforms detected in the parental strain.
Analysis of 276.4 and 276.4STF-The mutation in strain 276.4 has been characterized previously (26) . The mutation lies in lsgE, one of the seven genes in the lsg locus of H. influenzae (24, 25) . The inactivation of lsgE results in the expression of three major glycoforms of ϳ4.2, 4.4, and 5.4 kDa, a much simpler profile when compared with the parental strain A2 (Fig. 2A) . The 5.4-kDa glycoform is of particular interest to this study because it contains a terminal sialyl N-acetyllactosamine structure (26) . When treated with neuraminidase, the disap-pearance of the 5.4-kDa glycoform coincides with the appearance of a band of ϳ5.1 kDa, a 300-kDa shift corresponding to the loss of a single NeuAc residue (Fig. 2A) . The LOS was transferred to a nylon membrane and probed with the monoclonal antibody 3F11, which recognizes the terminal N-acetyllactosamine structure. If NeuAc or other sugars are present extending from this epitope, the binding of 3F11 is blocked. 3F11 was able to bind LOS from strain 276.4 only after neuraminidase treatment (Fig. 2B) . The binding corresponded to the 5.1-kDa glycoform. 3F11 binding to the 276.4 LOS before neuraminidase treatment could not be demonstrated by Western blotting, even after the blot was overexposed (Fig. 2C ). An insertional mutant in the siaA gene in strain 276.4 was constructed. Strain 276.4 was transformed using the MIV method (34) with pHS89-103K6, and transformants were obtained. kDa. Both the 5.1-and 5.8-kDa glycoforms were minor species and appear as faint bands when visualized with SDS-PAGE ( Fig. 2A ). When this sample was treated with neuraminidase, the 5.8-kDa glycoform shifted to ϳ5.4 kDa, indicating the loss of NeuAc. When the LOS was transferred to a nylon membrane and probed with 3F11, the antibody bound to the 5.1-kDa glycoform in the neuraminidase-treated 276.4STF LOS sample but with less intensity than the neuraminidase-treated 276.4 LOS sample (Fig. 2B) . After overexposure of the blot, 3F11 was also visualized binding to the 276.4STF LOS sample before neuraminidase treatment (Fig. 2C) . There was no antibody binding observed to the LOS of strain 276.4STF in the 5.4-kDa size range, even after the blot was overexposed (Fig. 2, B and C). These data indicated that although the 5.8-kDa glycoform contained NeuAc, it lacked a terminal N-acetyllactosamine structure. MALDI-MS analysis of these samples confirmed these results (discussed below).
Mutant Construction and MALDI Analysis of lic3A in Strains A2 and A2STF-The higher molecular weight sialylated species seen in both A2STF and 276.4STF indicated the possibility of a second sialyltransferase in this organism. Our analysis suggested that this second sialyltransferase would have a different specificity than a terminal N-acetyllactosamine structure. This was based on the fact that Western blot analysis with 3F11 indicated that this terminal structure was lost in the 276.4STF mutant, but sialylation was retained. Recently, a sialyltransferase was reported in a H. influenzae gene called lic3A, which is the first gene in the lic3 locus (20, 29) . This gene is phase-variable, and its protein product sialylates both lactose and N-acetyllactosamine in vitro but only sialylates lactose-containing structures in vivo (29) . Lic3A has around 40% identity to CstII from C. jejuni (29) . This protein in C. jejuni is a bifunctional sialyltransferase, with the ability to transfer NeuAc to terminal galactose residues as well as the O-8 position of terminal NeuAcs (30) . To investigate the possibility of Lic3A being the sialyltransferase responsible for sialylating the higher molecular weight species of A2STF, a mutation in lic3A was made in both strains A2 and A2STF. Primers were made to the DNA sequence upstream and downstream of HI0352, the lic3A homologue in Rd, based on the published H. influenzae Rd genomic sequence. A DNA fragment was PCR-amplified from strain A2 that was similar in size to the expected Rd fragment. This fragment was TAcloned, forming plasmid p0352EX. Both strands of the amplified DNA of p0352EX were sequenced and compared with the known sequences in the data base. The gene order in p0352EX was identical to that in Rd. Downstream from lic3A was the galE homologue HI0351 and the 5Ј portion of HI0350, a hypothetical membrane protein. Upstream from the lic3A gene was HI0354 and the 5Ј portion of HI0355. A nonpolar chloramphenicol cassette was inserted in the middle of lic3A, forming p0352EXCM. This construct was linearized and transformed into strains A2 and A2STF. Transformants from the A2 and A2STF transformation were named A2L3A and A2STFL3A, respectively. Proper insertion of the chloramphenicol cassette was confirmed with Southern hybridization (data not shown).
MALDI-TOF analysis of the LOS expressed by strain A2L3A revealed the loss of both the disialylated (H 2 **) and hexosecontaining (B 2 *, D 2 *, and E 2 *) species but confirmed the presence of the major sialylated species (H 1 *, H 2 * I 1 *, and H 2 *) observed in the parental strain A2 (Fig. 3, Table IV ). This indicated that in strain A2, the Lic3A homologue has substrate specificity distinct from SiaA, preferring to transfer NeuAc to LOS glycoforms devoid of N-acetylhexosamine. The loss of the disialylated glycoform H 2 ** may reflect the inability of the A2L3A mutant to sialylate one branch of the H 2 structure. The mass spectra of the LOS isolated from strain A2STFL3A revealed that the double mutant lost the ability to produce the SiaA products (H 1 *, H 2 * I 1 *, and H 2 *) containing N-acetylhexosamine (Fig. 3, Table IV ). Strain A2STFL3A did produce sialylated species (K 2 *, K 3 *, L 2 *, and L 3 *) that were not previously observed in either strain A2L3A or the parental strain A2 but were identified in strain A2STF. Since the deletion of both siaA and lic3A precludes the assembly of only certain subsets of NeuAc containing LOS glycoforms of H. influenzae strain A2, we conclude that their gene products function as sialyltransferases and infer the existence of a third sialyltransferase in this complex system.
Exoglycosidase Treatments of 276.4STF O-LOS-To investigate the structures of the extended glycoforms produced in the siaA mutants, experiments were conducted on the O-LOS from strain 276.4STF. The sialylated acceptor species in 276.4STF, designated J 3 *, is a minor component in the O-LOS mixture occurring at m/z ϳ3706 Da (Table V) . Compared with the sialylated G 2 * glycoform in O-LOS from strain 276.4 (Table V) , this species was ϳ324 -326 Da higher in molecular mass. Our initial assumption was that the added moiety was a Hex 2 extension (which would have corresponded to the same composition as the A2 wild-type I 2 * glycoform). However, dephosphorylation of the O-LOS sample with aqueous HF revealed that the novel acceptor species contained three PEAs, rather than the one or two PEAs present on all of the major components in the mixture. This observation indicated that the added structural pieces had to be HexNAc plus PEA (ϩ326 Da), rather than Hex 2 (ϩ324 Da).
To sequence the terminus of the J 3 * species, the O-LOS from strain 276.4STF was subjected to a series of exoglycosidase treatments and analyzed by MALDI-MS (data not shown). As a first step, the sample was treated with a mixture of three enzymes consisting of ␣-galactosidase, ␤-galactosidase, and ␤-N-acetylhexosaminidase. This treatment was done to ensure that any nonreducing terminal saccharides of this type that were not blocked by sialylation would be removed from the species before sequencing of the acceptor began. In the case of strain 276.4STF, the mixture treatment did not alter the glycoform profile of the sample except to remove a small peak for the G 2 species. However, when strain A2STFL3A O-LOS was subjected to the mixture treatment, various high molecular weight glycoforms were digested with the enzymes, such that the final profile of the strain A2STFL3A O-LOS population was virtually identical to the strain 276.4STF O-LOS profile, except for minor differences in the PEA content of the species. The high molecular weight sialylated glycoforms in the strain A2STFL3A sample (the K 2 */K 3 * and L 2 */L 3 * glycoforms given in Table IV ) were converted to the J 2 */J 3 * species by the loss of 1 and 2 galactoses, respectively. This indicated that the J 3 * species contained the essential structure of the novel acceptor branch found in the O-LOS from both the A2STFL3A and 276.4STF strains.
After the mixture treatment, the strain 276.4STF sample was neuraminidase-treated and then tested with a battery of exoglycosidases. Using this approach, none of the following enzymes were effective at removing a terminal sugar from the asialo acceptor: ␣-galactosidase, ␤-galactosidase, ␣-glucosidase, ␤-glucosidase, ␤-N-acetylhexosaminidase, and ␣-N-acetylgalactosaminidase.
As an alternate approach, the mixture-treated strain 276.4STF sample was subjected to dephosphorylation with aqueous HF prior to further enzymatic treatments. To minimize the loss of sialic acid in the dephosphorylation step, the reaction time was kept to Յ16 h. Under these conditions, microheterogeneity was created in the sample, with asialo and sialylated species appearing as pairs containing 0 or 1 residual phosphate group. When the HF-treated strain 276.4STF sample was subjected to ␣-N-acetylgalactosaminidase treatment, all of the asialo and sialylated glycoforms of the acceptor were shifted to lower mass by the loss of 203 Da, indicating the removal of an ␣-linked GalNAc (␣-GalNAc). At this point, the sample was split into two portions, one treated with ␤-galactosidase and one treated with neuraminidase followed by ␤-galactosidase. In the sample treated first with ␤-galactosidase, only the asialo glycoform was shifted, indicating the removal of ␤-linked galactose. The sialylated glycoform was shifted to the same species in a sequential fashion by neuraminidase treatment (Ϫ291 Da) followed by ␤-galactosidase treatment (Ϫ162 Da).
Cloning and Mutagenesis of lsgB-The lsgB has been previously described in the lsg locus of H. influenzae as orf2 (accession number Q48211) and in the TIGR H. influenzae Rd data base as ORF HI1699. It encodes a predicted protein of 304 amino acids. This protein sequence has 27% identity and 46% similarity along the entire length of the recently identified ␣2-3-sialyltransferase (Lst) protein from Neisseria gonorrhoeae and N. meningitidis (25, 33) . Lst is the sialyltransferase responsible for the addition of NeuAc to galactose of a terminal N-acetyllactosamine moiety of the LOS. To clone this gene for mutagenesis and transformation, a BbsI-PstI digest of the lsg locus in the plasmid pGEMLOS4 released a 2161-bp fragment. The plasmid was religated containing lsgA (lsg orf1), lsgB (lsg orf2), and lsgC (lsg orf3) and part of lsgD (lsg orf4). Using this construct, a deletion mutant was made in lsgB by deleting 506 bases with a BsrGI-XcmI digest of this fragment and inserting an erythromycin cassette. This cassette was placed in the forward orientation and does not contain a transcriptional termination sequence. The plasmid was linearized and transformed into strains A2 and A2STFL3A by the MIV method using appropriate selection. The resulting strains were designated A2lsgB and A2STFL3AlsgB. The chromosomal insertions were confirmed by PCR and Southern hybridization.
MALDI-TOF Analysis of A2lsgB and A2STFL3AlsgB-The O-deacylated LOS from the lsgB mutant (A2lsgB) and the triple mutant (A2STFL3AlsgB) were analyzed by MALDI mass spectrometry, both before and after neuraminidase treatment (Fig. 4) . The A2STFL3AlsgB triple mutant did not produce any of the sialylated LOS structures characteristic of the H. influenzae A2 strain; nor did it produce the novel sialylated species (K 2 *, K 3 *, L 2 *, and L 3 *) found in the siaA mutant (Fig. 1) and the siaA and lic3A double mutant (Fig. 3) . Additionally, the asialo forms of the novel acceptors (K 2 , K 3 , L 2 , and L 3 ) were not detected in the A2STFL3AlsgB O-LOS population. The only LOS modifications observed involved a shift to higher phosphorylation states. In addition to an increase in the relative amount of glycoforms containing two PEAs, a formerly minor series of glycoforms containing two PEAs plus an additional phosphate moiety was prominent in the A2STFL3AlsgB O-LOS population (Fig. 4) . Since this new series nearly coincided with some of the predicted masses for the asialo N-acetylhexosamine containing glycoforms (H 1 , H 2 , I 1 , and I 2 ), the A2STFL3AlsgB O-LOS was dephosphorylated with aqueous HF and reanalyzed by MALDI mass spectrometry. No significant peaks for the asialo N-acetylhexosamine acceptors were revealed in the dephosphorylated mixture (data not shown).
Like the A2STFL3AlsgB triple mutant, the lsgB mutant (A2lsgB) did not produce the asialo or sialylated forms of the novel LOS structures (K 2 , K 3 , L 2 , and L 3 ) found in the siaA mutants (Fig. 4) . Additionally, there was almost no detectable production of the sialyl-N-acetylhexosamine-containing glycoforms (H 1 *, H 2 *, H 2 **, I 1 *, and I 2 *) characteristic of the parental strain A2 (Fig. 4) . Only very minor peaks for the H 1 * and I 1 * glycoforms were detected by MALDI mass spectrometry. It was not possible to detect the asialo glycoforms of these acceptors (H 1 , H 2 , I 1 , and I 2 ) in the A2lsgB O-LOS mixture, but small peaks for the H 1 and I 1 acceptors were distinguished after neuraminidase treatment (Fig. 4) . While showing reduced production of the N-acetylhexosamine-containing glycoforms, the A2lsgB mutant was capable of expressing the hexose-containing sialylated species (B 1 *, B 2 *, D 2 *, E 1 *, and E 2 *) found in H. influenzae A2.
Whole-cell 3F11 ELISA-To more directly measure the level of sialylation of N-acetyllactosamine structures on the LOS of whole bacteria, a whole-cell ELISA assay was developed using the monoclonal antibody 3F11 (Fig. 5) . Because of the relatively low abundance of the sialylated glycoforms, this method gives greater sensitivity in the analysis of the N-acetyllactosamineterminating glycoforms. The parent strain A2, in the absence of neuraminidase, bound 3F11 poorly (Fig. 5) . When neuraminidase was added, 3F11 was able to bind with much greater efficiency, indicating the terminal N-acetyllactosamine con- taining glycoforms were substituted with NeuAc. Previous work by Hood et al. (28) showed that a mutation in siaB, a CMP-NeuAc synthetase, eliminated sialylation. When a siaB mutant (A2SB) was analyzed with this assay, the binding of 3F11 indicated that all of the N-acetyllactosamine was free of NeuAc; however, the binding was ϳ50% of that seen in strain A2 after neuraminidase treatment (Fig. 5) . This indicated that in the absence of sialylation, a population of the terminal N-acetyllactosamine was modified. In support of this, the MALDI-MS analysis of strain A2SB contained no sialylated glycoforms but did contain higher molecular weight glycoforms not found in strain A2. 5 The siaA mutant strain (A2STF), before neuraminidase treatment, reacted with 3F11 in a similar fashion as strain A2 before treatment with neuraminidase. After neuraminidase treatment, 3F11 binding to A2STF was reduced to 50% of that seen when neuraminidase-treated strain A2 was the target antigen. This decrease in binding between the neuraminidase-treated samples was similar to the difference in the level of binding between strain A2SB and the neuraminidase-treated strain A2 (Fig. 5) . This suggests that in strain A2STF, a population of the terminal N-acetyllactosamine was sialylated, and an additional population was modified, similar to that observed with strain A2SB. The MALDI-MS data from strain A2STF support the hypothesis that other sugars are added to the terminal N-acetyllactosamine. LOS from strain A2STF had a reduced amount of the sialylated N-acetylhexosamine-containing glycoforms (H 1 *, H 2 *, I 1 *, and I 2 *) when compared with the parental strain A2 (Fig. 1, Table III ). This change was not accompanied by an increase in the acceptor glycoforms (H 1 , H 2 , I 1 , and I 2 ) but rather higher molecular weight glycoforms (K 2 *, K 3 *, L 2 *, and L 3 *) that were extended by a HexNAc and a PEA moiety when compared with glycoforms H 1 *, H 2 *, I 1 *, and I 2 *. Further evidence that sugars are being added to the terminal N-acetyllactosamine comes from analysis of strain 276.4STF, which indicates that in a siaA mutant, the sugars are added to the terminal N-acetyllactosamine structure (Fig. 2) .
Our data combined with a previous study by Hood et al. (29) indicate that H. influenzae contains multiple sialyltransferases. It is conceivable that in the absence of one sialyltransferase, the other sialyltransferase could compensate by sialylating terminal structures not normally sialylated in the parental strain. We analyzed the lic3A mutant (A2L3A), which has been shown previously to be a sialyltransferase capable of sialylating both lactose and N-acetyllactosamine structures in vitro but only lactose structures in vivo (29) . Using the ELISA assay, strain A2L3A was similar to strain A2, regardless of neuraminidase treatment (Fig. 5 ). This indicated that lic3A was not responsible for sialylating N-acetyllactosamine structures in the parent strain A2. A double mutant in both siaA and lic3A (A2STFL3A) was analyzed before and after neuraminidase treatment. The binding of 3F11 was identical both before and after treatment with neuraminidase and was ϳ50% of that seen with the neuraminidase-treated parental strain A2 (Fig.  5 ). This result indicated that strain A2STFL3A lacked NeuAc on the terminal N-acetyllactosamine, and in a similar fashion to both strains A2SB and A2STF, a population of the terminal N-acetyllactosamine was further modified. The MALDI-MS analysis of strain A2STFL3A supports this contention (Fig. 3 , Table IV ). Strain A2STFL3A was completely devoid of the sialylated N-acetylhexosamine-containing glycoforms representing peaks H 1 *, H 2 *, I 1 *, and I 2 * but did contain peaks representing the acceptor glycoforms (H 1 , H 2 , I 1 , and I 2 ). This strain also contained higher molecular weight N-acetylhexosamine containing glycoforms modified by the addition of a HexNAc and a PEA moiety (K 2 *, K 3 *, L 2 *, and L 3 *) when compared with the N-acetylhexosamine-containing glycoforms designated by peaks H 1 *, H 2 *, I 1 *, and I 2 *. Both the ELISA assay and the MALDI-MS results of strain A2STFL3A indicated that the sialylation observed in the hexose-containing glycoforms in strain A2STF was the result of the second sialyltransferase, Lic3A. The 3F11 ELISA analysis of strain A2lsgB showed lower binding activity, similar to A2 prior to neuraminidase (Fig. 5) . After enzyme treatment, antibody binding to strain A2lsgB increases 4-fold, which is indicative of sialic acid release from N-acetyllactosamine. ELISA analysis of the triple mutant showed low levels of binding before and after neuraminidase treatment. This would indicate that all of the N-acetyllactosamine sites are not sialylated and that the levels of this acceptor are very low. This is confirmed by the MALDI data, which show a disappearance of the sialylated glycoforms and an inability to identify N-acetyllactosamine-containing glycoforms.
DISCUSSION
The biosynthesis of LOS is a complex process (5-9). Although previous investigations utilizing electrospray mass spectrometry revealed the presence of only two sialylated glycoforms in H. influenzae strain A2 (26) , MALDI-MS analysis of the LOS isolated from plate-grown organisms demonstrated eight LOS glycoforms terminating with NeuAc, including a disialylated species never observed before. This greater structural diversity of LOS seen in these MALDI-MS data can be attributed in part to advances made in mass spectrometry as well as an appreciation of the effects of glycoform biosynthesis when LOS is recovered from organisms grown on plates as opposed to broth culture (44) .
The goal of this study was to determine the roles of siaA and lsgB in the sialylation of H. influenzae LOS. From the evidence presented here, we conclude that both SiaA and LsgB function as sialyltransferases in strain A2. There are several lines of evidence that lead us to this conclusion. First, both proteins have high amino acid identity to previously described sialyltransferases and no other known glycosyltransferases. The ho- (33) . Second, mutations in siaA and lsgB only affect the sialylation of N-acetyllactosamine-containing glycoforms from stains A2 and 276.4. MALDI-MS analysis of LOS obtained from the siaA mutant strain A2STF showed that the sialylated N-acetyllactosamine-containing glycoforms that are composed of six and seven hexoses disappear and are replaced by a new set of sialylated glycoforms that are extended by the addition of a HexNAc and a PEA moiety. In order to eliminate the possibility that the effects seen by a mutation of siaA were caused by polar effects on downstream genes, the mutant was complemented. We developed a construct that would allow us to insert a functional siaA gene into the chromosome at a putative intergenic region. The LOS and ELISA profiles of the complemented mutant strain A2STFC.P4 were identical to the parental strain A2 (Fig. 1 , Table III ). This is clear evidence that the effects seen from the siaA mutants are the result of the inactivation of the siaA gene. The most likely explanation for the observation of novel sialylated glycoforms is that, in the absence of sialylation by SiaA, the HexNAc and PEA are added to the oligosaccharide branch and this new terminal structure is modified by sialic acid by yet another sialyltransferase (LsgB). Alternatively, it is possible that in the absence of SiaA, the HexNAc and PEA are added to a terminal branch other than the one containing sialic acid. The SDS-PAGE analysis of strain 276.4 and its siaA mutant strain 276.4STF show this is not the case (Fig. 2) . H. influenzae contains a triheptose core, and branched structures can be assembled from any of the three heptoses (15, 16, 45) . Strain 276.4 contains a mutation in lsgE, which results in a very defined LOS phenotype containing a single sialylated glycoform where the NeuAc extends from a terminal N-acetyllactosamine structure (26) . The siaA mutant strain 276.4STF contains only a very small amount of this glycoform but also produces a higher molecular weight sialylated glycoform extended by the addition of one HexNAc and one PEA moiety (Table V) . This extended glycoform did not bind to monoclonal antibody 3F11 after neuraminidase treatment, indicating that the 3F11 N-acetyllactosamine epitope had been modified, by the addition of the extra moieties.
The third line of evidence comes from analysis of the strains with a whole-cell ELISA assay using 3F11 (Fig. 5) . The parental strain A2 binds 3F11 minimally before neuraminidase treatment, but after treatment with neuraminidase the binding of 3F11 increased considerably, indicating that terminal N-acetyllactosamines were sialylated. Strain A2STF reacted in a similar fashion to strain A2, with the exception that the level of 3F11 binding after neuraminidase treatment was about 50% that of strain A2. This indicated that either the 3F11-positive glycoforms were not being produced in as great a quantity or that the 3F11 epitope was being modified. The difference in 3F11 binding of strain A2STF LOS before and after neuraminidase treatment indicated that although there was a decrease in the expression of the terminal N-acetyllactosamine epitope in this strain, it was still capable of being sialylated. A mutation in lic3A did not affect sialylation of N-acetyllactosamine as compared with the parent strain A2 using ELISA, but there was no sialylation detected in the siaA and lic3A double mutant by ELISA (Fig. 5) . The level of 3F11 binding in the siaA and lic3A double mutant was the same as that of the neuraminidase-treated A2STF strain and a sialylation-deficient siaB mutant strain (A2SB) (28). Hood et al. (28) showed that a mutation in siaB, a CMP-NeuAc synthetase gene, eliminated sialylation in NTHi strains. MALDI-MS of the LOS from this double mutant showed the presence of sialylated hexosamine-containing glycoforms. The failure of 3F11 to recognize these neuraminidase-treated glycoforms most probably reflects the fact that these new glycoforms have been altered in such a way that this antibody cannot bind. The appearance of novel HexNAcand PEA-containing higher molecular weight glycoforms observed by MALDI-MS supports the hypothesis that the previously available acceptor for sialic acid, N-acetyllactosamine, is modified.
Finally, a fourth line of evidence comes from studies conducted on the siaA, lic3A, and lsgB triple mutant (strain A2STFL3AlsgB). The presence of higher molecular weight sialylated species in the siaA and lic3A double mutant indicated that there had to be a third sialyltransferase in this system. The only other gene in H. influenzae with identity to a known sialyltransferase is lsgB. The LOS of strain A2STFL3AlsgB did not contain any sialylated glycoforms and did not produce any sialylated N-acetyllactosamine-containing glycoforms when analyzed with the ELISA assay (Figs. 4 and 5) , confirming LsgB as the third sialyltransferase.
LsgB would predictably have a different acceptor specificity from lactose or N-acetyllactosamine, since these structures are recognized by either lic3A or siaA. The siaA mutants have a HexNAc and a PEA moiety added to their structures, and in the case of 276.4STF, we know that this eliminates the N-acetyllactosamine epitope (Fig. 2) . To get a preliminary assessment of the structures of the novel acceptors in the siaA mutants, we conducted a series of exoglycosidase treatments on 276.4STF O-LOS. Mass spectrometric measurements indicated that that glycoform was related to the sialyl-N-acetyllactosamine-containing glycoform in strain 276.4 O-LOS by the addition of a HexNAc and a PEA moiety. Enzymatic digestions conducted on the 276.4STF O-LOS suggested that these structural pieces formed a new branch on the sialylated terminus. Once the sample was dephosphorylated, it could lose a nonreducing terminal ␣-GalNAc by treatment with ␣-N-acetylgalactosaminidase, suggesting that the added PEA moiety had been linked to the ␣-GalNAc residue. This ␣-GalNAc could be released from the acceptor both before and after desialylation, indicating that it was not the sugar being sialylated. Treatment of the species lacking ␣-GalNAc with ␤-galactosidase had no effect, whereas neuraminidase treatment followed by ␤-galactosidase treatment confirmed that the sialic acid was attached to a ␤-linked Gal residue. These findings suggest that the terminal galactose of the N-acetyllactosamine moiety found in the 276.4 O-LOS is glycosylated with both a sialic acid and an ␣-GalNAc bearing a PEA group in the novel extended acceptor expressed in strain 
276.4STF O-LOS.
Further experiments are in progress to fully characterize this unusual branched structure and the related sialylated glycoforms in strains A2STF and A2STFL3A.
Little is known about the role of NeuAc in regulation of LOS biosynthesis in Hemophilus. Our results indicate that in the absence of sialylation of terminal N-acetyllactosamine-containing glycoforms, they are being modified by the addition of a GalNAc and a PEA moiety. Vimr et al. (46) demonstrated, using an aldolase-deficient NeuAc mutant, that the level of sialylation was increased as compared with the parental strain. In this same study, it was observed that in defined media lacking NeuAc, the LOS on the bacteria lacked both sialylation and the 3F11 epitope. When NeuAc was added to the defined media, the 3F11 epitope was restored and the LOS was sialylated. The two possibilities that could explain this phenomenon are either lack of expression of the terminal N-acetyllactosamine-containing glycoform or a modification of this glycoform, eliminating the 3F11 epitope. Our SDS-PAGE and MALDI-MS analysis suggests that the latter explanation is true.
Sialylation has been studied in other mucosal pathogens, and its effects have varied from species to species. Sialylation in N. gonorrhoeae has probably been the most extensively studied of the mucosal pathogens. A single sialyltransferase has been identified in this organism, which requires an exogenous supply of CMP-NeuAc to sialylate its LOS (47) (48) (49) (50) . N. meningitidis contains two sialyltransferases, one for its poly-NeuAc capsule (51), which is found in all pathogenic strains, except serogroup A, and one responsible for sialylation of the LOS (48) . Both N. meningitidis and N. gonorrhoeae use a terminal N-acetyllactosamine as their NeuAc acceptor, but the sialyltransferase can use a number of different acceptor structures in vitro (27, 48, 52) . The Neisserial sialyltransferases have identity to lsgB, which is found in the lsg locus of H. influenzae (25) . Results presented here indicate that lsgB encodes a third sialyltransferase in this organism.
C. jejuni produces a number of sialylated lipopolysaccharide glycoforms, some of which mimic human gangliosides (30, (53) (54) (55) (56) . Two sialyltransferase genes have been identified in C. jejuni: cstI and cstII (30) . Both enzymes have high homology to one another but have different acceptor and linkage specificities. CstII is a bifunctional enzyme, responsible for both the transfer of NeuAc to terminal galactose residues as well as the O-8 position of terminal NeuAcs. The H. influenzae lic3A gene is 40% homologous at the protein level to cstII (29) . Hood et al. (29) showed that this enzyme from Haemophilus is capable of transferring NeuAc to a terminal lactose or an N-acetyllactosamine acceptor in vitro, but they reported that it is unable to modify more than one site on the LOS in vivo. Our results with MALDI-MS using strain A2L3A indicate that this gene is involved in the formation of a disialylated glycoform in strain A2 (Fig. 3, Table IV ). It is unclear, however, whether this disialylated species results from a NeuAc linked to the O-8 position of another NeuAc, similar to that seen in C. jejuni (30) , or if two different terminal galactose structures are sialylated on the same LOS glycoform. Preliminary evidence using the enzyme mixture indicates that two terminal branches are sialylated. Further structural studies are needed to answer this question.
In summary, our studies have revealed that three sialyltransferases with different specificities, lic3A, siaA, and lsgB, are involved in the sialylation of LOS glycoforms in H. influenzae strain A2. It would appear that when siaA is mutated, LOS biosynthetic pathways are altered such that a novel acceptor is formed that can be sialylated by LsgB. The presence of such redundancy to sialylate LOS structures in H. influenzae underscores the complexity of the system and indicates an important role for sialylation in the survival of this opportunistic pathogen.
